(Q49192661)

19 February 2018

title

MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. (English)

1 reference

19 February 2018

author name string

Ming Yang

1

1 reference

19 February 2018

Youyou Yan

2

1 reference

19 February 2018

Mingli Fang

3

1 reference

19 February 2018

Min Wan

4

1 reference

19 February 2018

Xiuli Wu

5

1 reference

19 February 2018

Xiaoling Zhang

6

1 reference

19 February 2018

Tiesuo Zhao

7

1 reference

19 February 2018

Hongfei Wei

8

1 reference

19 February 2018

Dandan Song

9

1 reference

19 February 2018

Liying Wang

10

1 reference

19 February 2018

Yongli Yu

11

1 reference

19 February 2018

publication date

14 May 2012

1 reference

19 February 2018

International Immunopharmacology

published in

1 reference

19 February 2018

volume

13

1 reference

19 February 2018

issue

4

1 reference

19 February 2018

page(s)

408-416

1 reference

19 February 2018

Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma.

cites work

1 reference

12 December 2020

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

1 reference

12 December 2020

MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020).

1 reference

12 December 2020

TLR-based immune adjuvants.

1 reference

12 December 2020

Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells

1 reference

12 December 2020

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

12 December 2020

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

1 reference

12 December 2020

Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major

1 reference

12 December 2020

Rapid and frequent induction of protective immunity exceeding UK recommendations for healthcare settings by MF59-adjuvated hepatitis B vaccine

1 reference

12 December 2020

Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs

1 reference

12 December 2020

Autoantibodies against cell surface GRP78 promote tumor growth in a murine model of melanoma

1 reference

12 December 2020

Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization

1 reference

12 December 2020

Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.

1 reference

12 December 2020

A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

1 reference

12 December 2020

Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo

1 reference

12 December 2020

Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity

1 reference

12 December 2020

A universal vaccine for serogroup B meningococcus

1 reference

12 December 2020

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans

1 reference

12 December 2020

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

1 reference

12 December 2020

Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

1 reference

12 December 2020

The path to a successful vaccine adjuvant--'the long and winding road'.

1 reference

12 December 2020

Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis

1 reference

12 December 2020

Vaccination with TCL plus MHSP65 induces anti-lung cancer immunity in mice

1 reference

12 December 2020

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

1 reference

12 December 2020

CpG-DNA aided cross-priming by cross-presenting B cells

1 reference

12 December 2020

Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival

1 reference

12 December 2020

Safety of MF59 adjuvant

1 reference

12 December 2020

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

12 December 2020

An alternative renewable source of squalene for use in emulsion adjuvants

1 reference

12 December 2020

Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome

1 reference

12 December 2020

Adjuvants for cancer vaccines

1 reference

12 December 2020

Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.

1 reference

12 December 2020

Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies

1 reference

12 December 2020

The perfect mix: recent progress in adjuvant research

1 reference

12 December 2020

Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12.

1 reference

12 December 2020

Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells

1 reference

12 December 2020

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.

1 reference

12 December 2020

Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses

1 reference

12 December 2020

Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity

1 reference

12 December 2020

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

1 reference

12 December 2020

The effectiveness of a CpG motif-based adjuvant (CpG ODN 2006) for LHRH immunization.

1 reference

12 December 2020

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

1 reference

12 December 2020

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

1 reference

12 December 2020

Therapeutic injection of C-class CpG ODN in draining lymph node area induces potent activation of immune cells and rejection of established breast cancer in mice

1 reference

12 December 2020

CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged.

1 reference

12 December 2020

10.1016/J.INTIMP.2012.05.003

Identifiers

DOI

1 reference

19 February 2018

PMC publication ID

7106219

0 references

1 reference

19 February 2018